Drugs / Menomune®
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT01239043 | Nov 2010 → Apr 2011 | meningococcal meningitis | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT00772070 | Mar → Aug 2003 | meningitis, meningococcemia | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 1/2 | NCT00874549 Comparator | Oct 2007 → Jan 2008 | meningococcal meningitis | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT00643916 Comparator | Dec 2004 → Mar 2006 | meningitis, meningococcal infection | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT00129129 Comparator | Aug 2004 → Sep 2005 | haemophilus infectious disease, meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Menomune | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00772070 ↗ |
| Modality | Vaccine | “Menomune® (a quadrivalent meningococcal A, C, Y, and W-135 plain polysaccharide vaccine licensed in the US)” NCT00129129 ↗ |
| Route | Subcutaneous | “Menomune™ was administered subcutaneously in the left deltoid region” NCT00129129 ↗ |